PMP2 Antibody

What is PMP2 and what is its biological significance?

PMP2, also known as peripheral myelin protein-2 or P2, is one of the major proteins found in peripheral nervous system (PNS) myelin. It constitutes up to 15% of total protein in peripheral myelin and appears to be related to the transport of fatty acids or the metabolism of myelin lipids . PMP2 is also present in small amounts in central nervous system myelin. The protein has a calculated molecular weight of 15 kDa based on its 132 amino acid sequence, although it is sometimes observed at 15-20 kDa in experimental conditions . Its biological significance primarily relates to myelin structure and lipid metabolism in peripheral nerves, with mutations in PMP2 being associated with demyelinating peripheral neuropathies such as Charcot-Marie-Tooth disease type 1 (CMT1) .

What types of PMP2 antibodies are available for research?

Based on the available research tools, PMP2 antibodies fall into two main categories:

Polyclonal antibodies are typically generated against recombinant fusion proteins containing sequences from human PMP2 . These antibodies recognize endogenous levels of total PMP2 protein . Monoclonal antibodies, such as E9S2A, are produced by immunizing animals with synthetic peptides corresponding to residues near the amino terminus of human PMP2 protein .

How specific are PMP2 antibodies, and what is their cross-reactivity profile?

PMP2 antibodies demonstrate good specificity for their target protein. According to validation data, commercial antibodies show reactivity with human, mouse, rat, and pig samples . Cross-reactivity has been confirmed in various tissues, including pig spinal cord tissue, human brain tissue, mouse testis tissue, and human gliomas tissue . The specificity of these antibodies has been validated through multiple techniques including Western blot and immunohistochemistry, with appropriate molecular weight detection (15-20 kDa) matching the predicted size of the PMP2 protein .

What are the optimal conditions for using PMP2 antibodies in Western blotting?

For optimal Western blotting results with PMP2 antibodies, the following conditions are recommended:

• Sample preparation: PMP2 is detectable in various tissues including brain, peripheral nerve, spinal cord, and some cases of adipose tissue.

• Gel conditions: 12% SDS-PAGE is suitable for resolving the relatively small (15 kDa) PMP2 protein .

• Recommended dilutions:

  • 1:500 - 1:2000 for polyclonal antibodies

  • Specific dilutions for monoclonal antibodies should be optimized per manufacturer recommendations

• Lysate loading: Approximately 40 μg of total protein is typically sufficient for detection .

• Detection conditions: Short exposure times (approximately 15 seconds) have been reported as sufficient for detection with appropriate secondary antibodies .

The antibody detects endogenous levels of total PMP2 protein at the expected molecular weight of 15-20 kDa .

How should PMP2 antibodies be used for immunohistochemistry (IHC)?

For successful immunohistochemical detection of PMP2:

• Sample preparation: Paraffin-embedded tissue sections are compatible with PMP2 antibodies.

• Antigen retrieval: TE buffer pH 9.0 is suggested for optimal antigen retrieval, although citrate buffer pH 6.0 may be used as an alternative .

• Antibody dilution: For polyclonal antibodies, a dilution range of 1:20 - 1:200 is recommended . Some specific antibodies may require more defined dilutions (e.g., 1:25) .

• Detection systems: Standard secondary antibody detection systems appropriate for rabbit-derived primary antibodies are compatible.

• Controls: Include positive controls such as peripheral nerve tissue where PMP2 is abundantly expressed.

PMP2 typically shows positive staining in myelinated structures, particularly in peripheral nerves and certain CNS regions .

What is the subcellular localization pattern of PMP2 when visualized by immunofluorescence?

In immunofluorescence studies, PMP2 typically shows a reticular distribution pattern in normal cells . In double immunostaining experiments, PMP2 can be visualized along with other cellular markers to understand its subcellular distribution:

• Normal distribution: PMP2-immunoreactive structures show reticular distribution patterns.

• Co-localization studies: PMP2 can be co-stained with organelle markers to determine its precise subcellular localization. For instance, Golgi markers (like FITC-conjugated Vicia Villosa Lectin) can help determine if PMP2 accumulates in this compartment .

• Pathological conditions: In certain conditions like CMT1A, PMP2 may form intracellular protein aggregates that can be visualized by immunofluorescence, which differs from the normal reticular pattern .

For optimal immunofluorescence results, fixation with 2% paraformaldehyde in 0.1 mol/L PBS for 20 minutes, followed by permeabilization with 0.2% Triton-X 100 in PBS for 10 minutes at room temperature (25°C) has been successfully employed .

What are common issues encountered when using PMP2 antibodies, and how can they be resolved?

Researchers may encounter several challenges when working with PMP2 antibodies:

• Weak signal in Western blots:

  • Increase antibody concentration (within recommended range)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Increase protein loading (up to 40-50 μg)

  • Use enhanced chemiluminescence detection systems

  • Optimize transfer conditions for small proteins (15 kDa)

• High background in immunohistochemistry:

  • Increase blocking time or blocking reagent concentration

  • Optimize antibody dilution (start with higher dilutions)

  • Ensure appropriate antigen retrieval (TE buffer pH 9.0 is recommended)

  • Decrease incubation time or temperature

• Cross-reactivity concerns:

  • Validate antibody specificity using PMP2 knockout/knockdown samples

  • Use multiple antibodies targeting different epitopes

  • Include appropriate negative controls

• Low reproducibility:

  • Aliquot antibodies to avoid freeze-thaw cycles

  • Store as recommended (typically -20°C)

  • For some antibodies, storage with glycerol (50%) and BSA (0.1%) may improve stability

How can researchers validate the specificity of PMP2 antibodies in their experimental system?

Validating antibody specificity is crucial for obtaining reliable results. For PMP2 antibodies, consider these validation approaches:

• Genetic validation:

  • Use samples from PMP2 knockout models or PMP2-depleted cells (siRNA/shRNA)

  • The absence of signal in these samples confirms specificity

• Peptide competition assays:

  • Pre-incubate the antibody with excess immunizing peptide

  • This should block specific binding and eliminate true signals

• Multiple antibody approach:

  • Use different antibodies targeting distinct epitopes of PMP2

  • Concordant results increase confidence in specificity

• Molecular weight verification:

  • Confirm that the detected band appears at the expected molecular weight (15-20 kDa)

  • Be aware that post-translational modifications may alter migration patterns

• Positive control tissues:

  • Include tissues known to express PMP2 (peripheral nerves, certain brain regions)

  • Validated sample types include pig spinal cord, human brain, and mouse testis

• Recombinant protein controls:

  • Use purified recombinant PMP2 protein as a positive control

  • This allows for assessing antibody sensitivity and specificity

How can PMP2 antibodies be used to study protein-protein interactions and complex formation?

Advanced applications of PMP2 antibodies in studying protein interactions include:

• Co-immunoprecipitation (Co-IP):

  • PMP2 antibodies can be used to pull down PMP2 and associated proteins

  • This approach can identify novel binding partners or confirm suspected interactions

  • Use mild lysis conditions to preserve protein complexes

  • Consider cross-linking to stabilize transient interactions

• Proximity ligation assay (PLA):

  • Combine PMP2 antibodies with antibodies against suspected interaction partners

  • This technique visualizes interactions that occur within 40 nm distance

  • Particularly useful for studying PMP2 interactions in situ

• Immunofluorescence co-localization:

  • Double immunostaining with PMP2 and other protein antibodies

  • Useful for examining subcellular co-localization patterns

  • Has been successfully employed with markers like LC3 and LAMP1

• Pull-down assays with recombinant proteins:

  • Use antibodies to validate interactions identified through other methods

  • Can confirm direct interactions observed in yeast two-hybrid or in vitro binding assays

• Cross-linking mass spectrometry:

  • Combine antibody-based purification with advanced mass spectrometry

  • Helps identify interaction interfaces and complex architecture

How can PMP2 antibodies be used to study Charcot-Marie-Tooth disease pathophysiology?

PMP2 antibodies are valuable tools for investigating Charcot-Marie-Tooth disease (CMT), particularly since mutations in PMP2 have been identified as causing CMT1 :

• Expression analysis in patient samples:

  • Compare PMP2 protein levels in affected vs. unaffected individuals

  • Study distribution patterns in patient-derived tissues or cultured cells

  • PMP2 antibodies can help determine if mutations affect protein stability or localization

• Mutation-specific effects:

  • Study the effects of specific mutations (p.Ile52Thr, p.Thr51Pro, p.Ile43Asn) on protein folding and localization

  • These mutations are found in highly conserved regions of the protein and may affect PMP2 structure-function

• Cell model systems:

  • Patient-derived fibroblasts show detectable phenotypes that can be studied with PMP2 antibodies

  • Similar to CMT1A (caused by PMP22 duplication), cells may show protein aggregates that can be visualized with antibodies

• Protein misfolding and aggregation:

  • PMP2 antibodies can detect and characterize protein aggregates

  • Co-staining with markers for cellular degradation pathways (proteasome, autophagy) can provide insights into disease mechanisms

• Structure-function relationships:

  • PMP2 mutations occur in regions forming the beta barrel structure of the protein

  • Antibodies can help determine if mutations affect protein stability or interactions with lipids and other molecules

What is the relationship between PMP2 and other myelin proteins in normal and pathological conditions?

PMP2 antibodies can help elucidate the complex interplay between different myelin proteins:

• Co-expression analysis:

  • Double immunostaining with PMP2 and other myelin protein antibodies

  • Helps determine spatial and temporal relationships during myelination and in disease states

• Compensatory mechanisms:

  • In PMP22-related CMT1A, alterations in PMP2 expression may occur

  • PMP2 antibodies can detect potential compensatory changes in PMP2 levels or distribution

• Degradation pathways:

  • When one myelin protein is abnormal (e.g., PMP22 overexpression in CMT1A), other proteins may be affected

  • Co-staining of PMP2 with autophagy-lysosomal proteins like LC3-II and LAMP1 can reveal pathway interactions

• Protein complex formation:

  • PMP2 may form complexes with other myelin proteins

  • Immunoprecipitation with PMP2 antibodies followed by analysis of co-precipitated proteins can identify such complexes

• Functional redundancy:

  • Some myelin proteins may have overlapping functions

  • Studying PMP2 in the context of other myelin protein alterations can reveal functional relationships

How can PMP2 antibodies contribute to understanding protein quality control mechanisms in myelinating cells?

PMP2 antibodies provide valuable insights into protein quality control mechanisms:

• Protein aggregation detection:

  • In CMT1A and potentially in PMP2-related CMT1, protein aggregation is a key pathological feature

  • PMP2 antibodies can detect aggregate formation and characterize their composition

• Autophagy pathway interactions:

  • Co-immunostaining with autophagy markers like LC3-II

  • Helps determine if PMP2 is processed through autophagy-lysosomal pathways

  • Research shows that abnormalities in myelin protein processing coincide with changes in autophagy markers

• Proteasome pathway analysis:

  • PMP2 antibodies can be used to study if proteasomal degradation is involved in PMP2 turnover

  • In CMT1A fibroblasts, cytosolic accumulation of myelin proteins coincides with decreased proteasome activity

• Endoplasmic reticulum stress responses:

  • Co-staining of PMP2 with ER stress markers

  • Helps determine if abnormal PMP2 processing induces ER stress

  • Particularly relevant for studying effects of PMP2 mutations

• Therapeutic intervention assessment:

  • PMP2 antibodies can be used to monitor changes in protein processing following experimental treatments

  • Helps evaluate if therapies targeting protein quality control pathways are effective